重症感染病原体分子检测的性能与经济性评价:EVAMICA 开放标签、整群随机、干预性交叉试验
该多中心、开放标签、整群随机交叉试验在连续两个阶段内将患者随机分配至对照期(标准诊断流程)或干预期(加做 LightCycler®SeptiFast 分子检测),按重症脓毒症(SES)、发热性中性粒细胞减少(FN)和疑似感染性心内膜炎(SIE)分层分析。共1416例患者纳入主要终点(血病原学诊断率)评价,其中SES 907例、FN 440例、SIE 69例。SES患者在干预期的血病原学诊断率高于对照期(42.6% vs 28.1%,OR 1.89,95%CI 1.43-2.50,P<0.001),绝对增加14.5%(95%CI 8.4-20.7);SIE呈关联趋势(35.4% vs 9.5%,OR 6.22,95%CI 0.98-39.6),FN无差异(32.1% vs 30.2%,P=0.66)。总体报告时间干预期短于对照期(22.9 vs 49.5 h,P<0.001),住院费用相近,SES患者中干预具有弱优势。
要点
- SES患者加做分子检测后血病原学诊断率42.6%(198/465)vs 对照期28.1%(125/442),OR 1.89(95%CI 1.43-2.50),绝对增加14.5%(95%CI 8.4-20.7)。
- SIE患者诊断率35.4%(17/48)vs 9.5%(2/21),OR 6.22(95%CI 0.98-39.6),仅为趋势关联。
- FN患者诊断率32.1%(70/218)vs 30.2%(67/222),P=0.66,无显著差异。
- 总体报告时间干预期22.9 h vs 对照期49.5 h,P<0.001。
- 住院费用相近:干预期中位数€14,826、均值±SD €18,118±17,775;对照期中位数€17,828、均值±SD €18,653±15,966;SES患者中干预呈弱优势。
适用人群与场景
- 重症脓毒症(SES)、发热性中性粒细胞减少(FN)、疑似感染性心内膜炎(SIE)患者,多中心住院场景。
处置流程与药物剂量
- 对照期采用标准诊断流程;干预期在标准诊断流程基础上加做 LightCycler®SeptiFast 分子检测。
研究设计与关键结果
- 多中心、开放标签、整群随机、干预性交叉试验,两阶段随机分配为对照期或干预期,按SES、FN、SIE分层。
- 共1416例患者评价主要终点(血病原学诊断率):SES 907例、FN 440例、SIE 69例。
- SES患者诊断率干预期42.6%(198/465)vs 对照期28.1%(125/442),OR 1.89(95%CI 1.43-2.50),P<0.001,绝对增加14.5%(95%CI 8.4-20.7)。
- SIE患者诊断率干预期35.4%(17/48)vs 对照期9.5%(2/21),OR 6.22(95%CI 0.98-39.6),呈关联趋势。
- FN患者诊断率干预期32.1%(70/218)vs 对照期30.2%(67/222),P=0.66,无显著差异。
- 总体报告时间干预期22.9 h vs 对照期49.5 h,P<0.001。
- 住院费用:干预期中位数€14,826、均值±SD €18,118±17,775;对照期中位数€17,828、均值±SD €18,653±15,966;SES患者中干预呈弱优势。
证据类型、等级与局限
- 证据类型:多中心、开放标签、整群随机、干预性交叉试验(ClinicalTrials.gov NCT00709358)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对重症脓毒症患者,在标准诊断流程基础上加做分子检测可提高血病原学诊断率并缩短报告时间;FN患者未见诊断率提高;SIE仅为趋势关联。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Microbiological diagnosis (MD) of infections remains insufficient. The resulting empirical antimicrobial therapy leads to multidrug resistance and inappropriate treatments. We therefore evaluated the cost-effectiveness of direct molecular detection of pathogens in blood for patients with severe sepsis (SES), febrile neutropenia (FN) and suspected infective endocarditis (SIE).
METHODS: Patients were enrolled in a multicentre, open-label, cluster-randomised crossover trial conducted during two consecutive periods, randomly assigned as control period (CP; standard diagnostic workup) or intervention period (IP; additional testing with LightCycler®SeptiFast). Multilevel models used to account for clustering were stratified by clinical setting (SES, FN, SIE).
RESULTS: A total of 1416 patients (907 SES, 440 FN, 69 SIE) were evaluated for the primary endpoint (rate of blood MD). For SES patients, the MD rate was higher during IP than during CP [42.6% (198/465) vs. 28.1% (125/442), odds ratio (OR) 1.89, 95% confidence interval (CI) 1.43-2.50; P < 0.001], with an absolute increase of 14.5% (95% CI 8.4-20.7). A trend towards an association was observed for SIE [35.4% (17/48) vs. 9.5% (2/21); OR 6.22 (0.98-39.6)], but not for FN [32.1% (70/218) vs. 30.2% (67/222), P = 0.66]. Overall, turn-around time was shorter during IP than during CP (22.9 vs. 49.5 h, P < 0.001) and hospital costs were similar (median, mean ± SD: IP €14,826, €18,118 ± 17,775; CP €17,828, €18,653 ± 15,966). Bootstrap analysis of the incremental cost-effectiveness ratio showed weak dominance of intervention in SES patients.
CONCLUSION: Addition of molecular detection to standard care improves MD and thus efficiency of healthcare resource usage in patients with SES. ClinicalTrials.gov registration number: NCT00709358.
参考来源
- Cambau E, Durand-Zaleski I, Bretagne S, et al. Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial. Intensive Care Med. 2017. PMID: 28374097. doi:10.1007/s00134-017-4766-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。